prikaz prve stranice dokumenta The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response
  Preuzmi
PDF 833.62 KB
Znanstveni rad - Pregledni rad
The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response
Current Research in Pharmacology and Drug Discovery, 2 (2021); 100064. https://doi.org/10.1016/j.crphar.2021.100064
Migo, William; Bošković, Marko; Likić, Robert

Povezani objekti
COVID-19 | Virtualna zbirka
Citirajte ovaj rad

Migo, W., Bošković, M. i Likić, R. (2021). The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response. Current Research in Pharmacology and Drug Discovery, 2.. doi: 10.1016/j.crphar.2021.100064

Migo, William, et al. "The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response." Current Research in Pharmacology and Drug Discovery, vol. 2, 2021. https://doi.org/10.1016/j.crphar.2021.100064

Migo, William, Marko Bošković i Robert Likić. "The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response." Current Research in Pharmacology and Drug Discovery 2 (2021). https://doi.org/10.1016/j.crphar.2021.100064

Migo, W., Bošković, M. i Likić, R. (2021) 'The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response', Current Research in Pharmacology and Drug Discovery, 2. doi: 10.1016/j.crphar.2021.100064

Migo W, Bošković M, Likić R. The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response. Current Research in Pharmacology and Drug Discovery [Internet]. 2021. [pristupljeno 08.11.2024.];2. doi: 10.1016/j.crphar.2021.100064

W. Migo, M. Bošković i R. Likić, "The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response", Current Research in Pharmacology and Drug Discovery, vol. 2, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:760242. [Citirano: 08.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:760242
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response
AutorWilliam Migo
AutorMarko Bošković
AutorRobert Likić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Development of novel antibodies to combat the novel SARS-CoV-2 virus is ongoing. Importantly, particular subgroups are more prone to severe disease, namely patients with poor immune responses. This includes cancer patients with solid and haematological disease, solid organ transplant (SOT) patients and those with congenital or acquired immunodeficiency. Outcomes for patients with poor immune responses receiving antibody therapy for underlying disease and SARS-CoV-2 severe infection are undergoing investigation. The objective of this study was to perform a search on patients with poor immune responses with severe SARS-CoV-2 infection, to assess if antibody therapy is beneficial in such populations. We performed searches using PubMED and medrXiv up to May 2021 of patients with solid and hematologic malignancy, SOT patients and acquired or congenital immunodeficiency. The primary outcome was to assess if antibody therapy was included during SARS-CoV-2 infection and the clinical outcomes of such treatment in this population. Here we find that there is a repurposing of monoclonal antibodies to target cytokine release syndrome, along with the use of convalescent plasma (CP). Despite CP demonstrating promising results, we reiterate evidence that CP forces mutational escape and subsequent variant development. Repurposing of antibody therapies (such as Tocilizumab) proved effective, especially in SOT patients. This also potentially opens an avenue for the use of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies; however, studies have yet to focus on patients with poor immune responses as a subpopulation.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCurrent Research in Pharmacology and Drug Discovery
Brojčani podacivol. 2, 100064
p-ISSN2590-2571
DOIhttps://doi.org/10.1016/j.crphar.2021.100064
URN:NBNurn:nbn:hr:105:760242
Datum objave publikacije2021
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S2590257121000511
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-02-03 10:05:50